收费全文 | 269316篇 |
免费 | 18446篇 |
国内免费 | 1033篇 |
耳鼻咽喉 | 2987篇 |
儿科学 | 6911篇 |
妇产科学 | 5118篇 |
基础医学 | 34228篇 |
口腔科学 | 5640篇 |
临床医学 | 27971篇 |
内科学 | 56304篇 |
皮肤病学 | 3608篇 |
神经病学 | 26406篇 |
特种医学 | 11290篇 |
外国民族医学 | 15篇 |
外科学 | 41495篇 |
综合类 | 3424篇 |
现状与发展 | 1篇 |
一般理论 | 206篇 |
预防医学 | 20202篇 |
眼科学 | 6474篇 |
药学 | 18138篇 |
2篇 | |
中国医学 | 343篇 |
肿瘤学 | 18032篇 |
2023年 | 1443篇 |
2022年 | 2387篇 |
2021年 | 5780篇 |
2020年 | 3343篇 |
2019年 | 5554篇 |
2018年 | 6590篇 |
2017年 | 4842篇 |
2016年 | 5276篇 |
2015年 | 6254篇 |
2014年 | 9075篇 |
2013年 | 12341篇 |
2012年 | 18758篇 |
2011年 | 19604篇 |
2010年 | 10920篇 |
2009年 | 10148篇 |
2008年 | 17260篇 |
2007年 | 18149篇 |
2006年 | 17578篇 |
2005年 | 17497篇 |
2004年 | 16424篇 |
2003年 | 15047篇 |
2002年 | 14419篇 |
2001年 | 3004篇 |
2000年 | 2567篇 |
1999年 | 3042篇 |
1998年 | 3140篇 |
1997年 | 2508篇 |
1996年 | 2257篇 |
1995年 | 2077篇 |
1994年 | 1843篇 |
1993年 | 1807篇 |
1992年 | 1825篇 |
1991年 | 1753篇 |
1990年 | 1638篇 |
1989年 | 1505篇 |
1988年 | 1400篇 |
1987年 | 1337篇 |
1986年 | 1312篇 |
1985年 | 1377篇 |
1984年 | 1422篇 |
1983年 | 1262篇 |
1982年 | 1326篇 |
1981年 | 1272篇 |
1980年 | 1119篇 |
1979年 | 925篇 |
1978年 | 885篇 |
1977年 | 744篇 |
1976年 | 696篇 |
1974年 | 682篇 |
1973年 | 623篇 |
Background
The optimal noninvasive test (NIT) for patients with diabetes and stable symptoms of coronary artery disease (CAD) is unknown.Objectives
The purpose of this study was to assess whether a diagnostic strategy based on coronary computed tomographic angiography (CTA) is superior to functional stress testing in reducing adverse cardiovascular (CV) outcomes (CV death or myocardial infarction [MI]) among symptomatic patients with diabetes.Methods
PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) was a randomized trial evaluating an initial strategy of CTA versus functional testing in stable outpatients with symptoms suggestive of CAD. The study compared CV outcomes in patients with diabetes (n = 1,908 [21%]) and without diabetes (n = 7,058 [79%]) based on their randomization to CTA or functional testing.Results
Patients with diabetes (vs. without) were similar in age (median 61 years vs. 60 years) and sex (female 54% vs. 52%) but had a greater burden of CV comorbidities. Patients with diabetes who underwent CTA had a lower risk of CV death/MI compared with functional stress testing (CTA: 1.1% [10 of 936] vs. stress testing: 2.6% [25 of 972]; adjusted hazard ratio: 0.38; 95% confidence interval: 0.18 to 0.79; p = 0.01). There was no significant difference in nondiabetic patients (CTA: 1.4% [50 of 3,564] vs. stress testing: 1.3% [45 of 3,494]; adjusted hazard ratio: 1.03; 95% confidence interval: 0.69 to 1.54; p = 0.887; interaction term for diabetes p value = 0.02).Conclusions
In diabetic patients presenting with stable chest pain, a CTA strategy resulted in fewer adverse CV outcomes than a functional testing strategy. CTA may be considered as the initial diagnostic strategy in this subgroup. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550) 相似文献Areas covered: This review provides an overview of existing pharmacotherapy for osteoporosis in women and explore state-of–the-art and emerging therapies to prevent bone loss, with an emphasis on the mechanism of action, indications and side effects.
Expert opinion: Bisphosphonates appear to be a reliable and cost-effective option, whereas denosumab has introduced a simpler dosing regimen and may achieve a linear increase in bone mineral density (BMD) with no plateau being observed, along with continuous anti-fracture efficacy. Abaloparatide, a parathyroid-hormone-related peptide (PTHrP)-analogue, approved by the FDA in April 2017, constitutes the first new anabolic osteoporosis drug in the US for nearly 15 years and has also proven its anti-fracture efficacy. Romosozumab, a sclerostin inhibitor, which induces bone formation and suppresses bone resorption, has also been developed and shown a significant reduction in fracture incidence; however, concerns have arisen with regard to increased cardiovascular risk. 相似文献